{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:31:02Z","timestamp":1648841462559},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1007\/s00108-005-1452-3","type":"journal-article","created":{"date-parts":[[2005,6,29]],"date-time":"2005-06-29T11:41:56Z","timestamp":1120045316000},"page":"873-881","source":"Crossref","is-referenced-by-count":0,"title":["H\u00e4mostaseologie"],"prefix":"10.1007","volume":"46","author":[{"given":"K.","family":"Schr\u00f6r","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1452_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic","year":"2002","unstructured":"Antithrombotic Trialists\u2018 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71\u201386","journal-title":"BMJ"},{"key":"1452_CR2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.103.2.201","volume":"103","author":"Chew","year":"2001","unstructured":"Chew DP, Bhatt DL, Sapp S, Topol EJ (2001) Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists. A meta-analysis of phase III multicenter randomized trials. Circulation 103: 201\u2013206","journal-title":"Circulation"},{"key":"1452_CR3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/B:THRO.0000014593.16147.bf","volume":"16","author":"Davidson","year":"2004","unstructured":"Davidson BL (2004) Preparing for new anticoagulants. J Thromb Thrombol 16: 49\u201354","journal-title":"J Thromb Thrombol"},{"key":"1452_CR4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(02)07495-0","volume":"359","author":"Direct","year":"2002","unstructured":"Direct Thrombin Inhibitor Trialists\u2018 Collaborative Group (2002). Direct thrombin inhibitors in acute coronary syndromes: principal results of a metaanalysis based on individual patients\u2018 data. Lancet 359: 294\u2013302","journal-title":"Lancet"},{"key":"1452_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2002-20562","volume":"28","author":"Francis","year":"2002","unstructured":"Francis JL, Amirkhosravi A (2002) Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 28: 29\u201338","journal-title":"Semin Thromb Hemost"},{"key":"1452_CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","volume":"101","author":"Gustafsson","year":"2001","unstructured":"Gustafsson D, Nystrom J, Carlsson S et al. (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101: 171\u2013181","journal-title":"Thromb Res"},{"key":"1452_CR7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0037-1613209","volume":"88","author":"Heemskerk","year":"2002","unstructured":"Heemskerk JWM, Bevers EM, Lindhout T (2002) Platelet activation and blood coagulation. Thromb Haemost 88: 186\u2013193","journal-title":"Thromb Haemost"},{"key":"1452_CR8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/09537100020031207","volume":"12","author":"Hermann","year":"2001","unstructured":"Hermann A, Rauch BR, Braun M, Schr\u00f6r K, Weber AA (2001) Platelet CD40 ligand (CD40L) \u2014 subcellular localization, regulation of expression and inhibition by clopidogrel. Platelets 12: 74\u201382","journal-title":"Platelets"},{"key":"1452_CR9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9149(02)02329-9","volume":"89","author":"Herrmann","year":"2002","unstructured":"Herrmann HC, Swierkosz TA, Kapoor S et al. (2002) Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 89: 1293\u20131297","journal-title":"Am J Cardiol"},{"key":"1452_CR10","doi-asserted-by":"crossref","first-page":"445S","DOI":"10.1378\/chest.114.5_Supplement.445S","volume":"114","author":"Hirsh","year":"1998","unstructured":"Hirsh J, Dalen JE, Anderson DR et al. (1998) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114 (Suppl 5): 445S\u2013469S","journal-title":"Chest"},{"key":"1452_CR11","unstructured":"Hohlfeld T, Schr\u00f6r K (2003) Thrombozytenaggregationshemmer, Heparine, Hirudine, Vitamin K-Antagonisten, Thrombolytika. In: B\u00f6hm M, Eschenhagen T (Hrsg) Arzneimitteltherapie kardiovaskul\u00e4rer Erkrankungen. Wiss. Verlagsgesellschaft, Stuttgart, S 210\u2013230"},{"key":"1452_CR12","unstructured":"Hohlfeld T (2004) Pharmacology of aspirin resistance. In: Schr\u00f6r K (ed) Aspirin \u2014 \u201eresistance\u201c or \u201enonresponsiveness\u201c. Dr.Schr\u00f6r-Verlag, Frechen, pp 17\u201332"},{"key":"1452_CR13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.fjc.0000154373.80659.38","volume":"45","author":"Kokolis","year":"2005","unstructured":"Kokolis S, Clark LT, Cavusoglu E, Marmur JD (2005) Direct thrombin inhibitor use during percutaneous coronary intervention. J Cardiovasc Pharmacol 45: 270\u2013279","journal-title":"J Cardiovasc Pharmacol"},{"key":"1452_CR14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1471-4892(01)00033-9","volume":"1","author":"Leadley","year":"2001","unstructured":"Leadley RJ, Chi L, Procari AR (2001) Non-hemostatic activity of coagulation factor Xa: Potential implications for various diseases. Curr Opin Pharmacol 1: 169\u2013175","journal-title":"Curr Opin Pharmacol"},{"key":"1452_CR15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2003-05-1385","volume":"103","author":"Leon","year":"2004","unstructured":"Leon C, Alex M, Klocke A et al. (2004) Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 103: 594\u2013600","journal-title":"Blood"},{"key":"1452_CR16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1515\/BC.2002.130","volume":"383","author":"Mueller","year":"2002","unstructured":"Mueller MM, Sperl S, St\u00fcrzebecher J (2002) (R)-3-amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode. Biol Chem 383: 1185\u20131191","journal-title":"Biol Chem"},{"key":"1452_CR17","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1161\/01.ATV.19.12.2835","volume":"19","author":"Nurden","year":"1999","unstructured":"Nurden AT, Poujol C, Durrieu-Jais C, Nurden P (1999) Platelet glycoprotein IIb\/IIIa inhibitors. Basic and clinical aspects. Arterioscler Thromb Vasc Biol 19: 2835\u20132840","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1452_CR18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.0000046487.06811.5E","volume":"107","author":"Ottervanger","year":"2003","unstructured":"Ottervanger JP, Armstrong P, Barnathan ES et al.; GUSTO IV-ACS Investigators (2003) Long-term results after the glycoprotein IIb\/IIIa inhibitor abciximab in unstable angina. Circulation 107: 437\u2013442","journal-title":"Circulation"},{"key":"1452_CR19","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","volume":"119","author":"Patrono","year":"2001","unstructured":"Patrono C, Coller B, Dalen JE et al. (2001) Platelet-active dugs. The relationships among dose, effectiveness, and side effects. Chest 119 (Suppl 1): 39S\u201363S","journal-title":"Chest"},{"key":"1452_CR20","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1182\/blood.V92.9.3240","volume":"92","author":"Peter","year":"1998","unstructured":"Peter K, Schwarz M, Ylanne J et al. (1998) Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb\/IIIa (alphaIIb\/beta3) inhibitors. Blood 92: 3240\u20133249","journal-title":"Blood"},{"key":"1452_CR21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.92.4.962","volume":"92","author":"Prager","year":"1995","unstructured":"Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR (1995) Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 92: 962\u2013967","journal-title":"Circulation"},{"key":"1452_CR22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/0929867013373822","volume":"8","author":"Rai","year":"2001","unstructured":"Rai R, Sprengeler PA, Elrod KC, Young WB (2001) Perspectives on factor Xa inhibition. Curr Med Chem 8: 101\u2013119","journal-title":"Curr Med Chem"},{"key":"1452_CR23","first-page":"d1915","volume":"7","author":"Rosen","year":"2002","unstructured":"Rosen ED (2002). Gene targeting in hemostasis \u2014 Factor X. Front Biosci 7: d1915\u2013d1925","journal-title":"Front Biosci"},{"key":"1452_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2003-40746","volume":"3","author":"Schr","year":"2003","unstructured":"Schr\u00f6r K, Gawaz M (2003) Antiplatelet and anticoagulant agents in cardiovascular disease: Basic research and clinical applications. Sem Vasc Med 3: 93\u2013213","journal-title":"Sem Vasc Med"},{"key":"1452_CR25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","volume":"23","author":"Schr","year":"1997","unstructured":"Schr\u00f6r K (1997) Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Haemost 23: 349\u2013356","journal-title":"Semin Thromb Haemost"},{"key":"1452_CR26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/B:THRO.0000003308.63022.8d","volume":"15","author":"Schr","year":"2003","unstructured":"Schr\u00f6r K, Weber A-A (2003) Comparative pharmacology of GPIIb\/IIIa antagonists. J Thromb Thrombol 15: 71\u201380","journal-title":"J Thromb Thrombol"},{"key":"1452_CR27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107602960100700303","volume":"7","author":"Van","year":"2001","unstructured":"Van Aken H, Bode C, Darius H et al. (2001) Anticoagulation: The present and future. Clin Appl Thromb Hemost 7: 195\u2013204","journal-title":"Clin Appl Thromb Hemost"},{"key":"1452_CR28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/09537100120104890","volume":"13","author":"Weber","year":"2002","unstructured":"Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schr\u00f6r K (2002) Towards a definition of aspirin resistance: a typological approach. Platelets 13: 37\u201340","journal-title":"Platelets"},{"key":"1452_CR29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0049-3848(02)00083-X","volume":"106","author":"Weber","year":"2002","unstructured":"Weber AA, Meila D, Jacobs C et al. (2002) Low incidence of paradoxical platelet activation by glycoprotein IIb\/IIIa inhibitors. Thromb Res 106: 25\u201329","journal-title":"Thromb Res"},{"key":"1452_CR30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0021-9150(99)00479-7","volume":"149","author":"Zaman","year":"2000","unstructured":"Zaman AG, Herlft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149: 251\u2013266","journal-title":"Atherosclerosis"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1452-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-005-1452-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1452-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T01:59:26Z","timestamp":1586311166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-005-1452-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1007\/s00108-005-1452-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}